Avacopan (CCX168)

Catalog No.S0474

For research use only.

Avacopan (CCX168) is an orally administered and selective C5a receptor (C5aR) antagonist.

Avacopan (CCX168) Chemical Structure

CAS No. 1346623-17-3

Selleck's Avacopan (CCX168) has been cited by 1 Publication

Purity & Quality Control

Choose Selective Immunology & Inflammation related Inhibitors

Biological Activity

Description Avacopan (CCX168) is an orally administered and selective C5a receptor (C5aR) antagonist.
C5aR [1]

Protocol (from reference)

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 581.64


CAS No. 1346623-17-3
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC1=C(C(=CC=C1)F)C(=O)N2CCCC(C2C3=CC=C(C=C3)NC4CCCC4)C(=O)NC5=CC(=C(C=C5)C)C(F)(F)F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02464891 Terminated Drug: CCX168 Atypical Hemolytic Uremic Syndrome Mario Negri Institute for Pharmacological Research|ChemoCentryx June 4 2015 Phase 2
NCT02384317 Completed Drug: CCX168 Immunoglobulin A Nephropathy ChemoCentryx February 2015 Phase 2

(data from https://clinicaltrials.gov, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Avacopan (CCX168) | Avacopan (CCX168) supplier | purchase Avacopan (CCX168) | Avacopan (CCX168) cost | Avacopan (CCX168) manufacturer | order Avacopan (CCX168) | Avacopan (CCX168) distributor